KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects

Chiao Xin Lim, Michael G Ricos, Leanne M Dibbens, Sarah E Heron

Epilepsy Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research and Centre for Cancer Biology, University of South Australia, Adelaide, South Australia, Australia

Correspondence to
Dr Sarah E Heron, School of Pharmacy and Medical Sciences, University of South Australia, P4-47, City East Campus, GPO Box 2471, Adelaide, SA 5001, Australia; sarah.heron@unisa.edu.au

ABSTRACT

Mutations in the sodium-gated potassium channel subunit gene KCNT1 have recently emerged as a cause of several different epileptic disorders. This review describes the mutational and phenotypic spectrum associated with the gene and discusses the comorbidities found in patients, which include intellectual disability and psychiatric features. The gene may also be linked with cardiac disorders. KCNT1 missense mutations have been found in 39% of patients with the epileptic encephalopathy malignant migrating focal seizures of infancy (MMFSI), making it the most significant MMFSI disease-causing gene identified to date. Mutations in KCNT1 have also been described in eight unrelated cases of sporadic and familial autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE). These patients have a high frequency of associated intellectual disability and psychiatric features. Two mutations in KCNT1 have been associated with both ADNFLE and MMFSI, suggesting that the genotype–phenotype relationship for KCNT1 mutations is not straightforward. Mutations have also been described in several patients with infantile epileptic encephalopathies other than MMFSI. Notably, all mutations in KCNT1 described to date are missense mutations, and electrophysiological studies have shown that they result in increased potassium current. Together, these genetic and electrophysiological studies raise the possibility of delivering precision medicine by treating patients with KCNT1 mutations using drugs that alter the action of potassium channels to specifically target the biological effects of their disease-causing mutation. Such trials are now in progress. Better understanding of the mechanisms underlying KCNT1-related disease will produce further improvements in treatment of the associated severe seizure disorders.

INTRODUCTION

Human KCNT1, which was first molecularly described in 2000,[1] encodes a sodium-gated potassium channel subunit also known as Sequence Like a Calcium Activated K+ channel (SLACK), $K_{Ca}4.1$ or Slo2.2.[2] The gene is highly expressed in the nervous system, and the encoded ion channel is thought to modulate hyperpolarisation following repetitive firing of action potentials.[3 4] The first disease-causing mutations in KCNT1 were described in 2012 and were shown to cause two distinctly different types of epilepsy: the familial focal epilepsy syndrome autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE)[5] and the epileptic encephalopathy malignant migrating focal seizures of infancy (MMFSI).[6] The phenotypic spectrum associated with KCNT1 mutations has since expanded to include other forms of focal epilepsy and epileptic encephalopathies. KCNT1 mutations may also be associated with cardiac arrhythmias.

KCNT1 MUTATIONS IN MMFSI

MMFSI, also known as epilepsy of infancy with migrating focal seizures, is an early-onset epileptic encephalopathy (EOEE) characterised by migrating multifocal seizures with onset before 6 months of age.[7] Seizures are intractable to antiepileptic drugs, and patients experience severe psychomotor developmental delay.[7] Barcia et al[6] first identified de novo KCNT1 mutations in individuals with MMFSI using whole-exome sequencing (WES) and subsequently identified additional patients by direct Sanger sequencing. Subsequent studies using whole-exome, whole-genome or gene panel sequencing approaches in MMFSI and EOEE cohorts identified additional KCNT1 mutations in patients with MMFSI[8–16] (figure 1 and table 1).

KCNT1 mutations have emerged as the most frequent genetic cause of MMFSI. Ten reports describing a total of 34 unrelated individuals with MMFSI with KCNT1 mutations have now been published[6 8–16] (figure 1 and table 1). Twenty-four of these patients were confirmed to have de novo mutations, explaining why most cases occur in the absence of a family history. Importantly, parental somatic mosaicism of a KCNT1 mutation has been demonstrated in two cases,[14 15] showing that there is a risk of recurrence of the disorder, where more than one child in a sibship could be affected, even if the parents are asymptomatic. Detection of parental somatic mosaicism of KCNT1 mutations is, therefore, important for genetic counselling of patients and their families.

To date, 39% (28 out of 71) of individuals from cohorts of patients with MMFSI that have been analysed for KCNT1 mutations are mutation positive.[6 10 12 14 15 17] The high frequency of mutations is in striking contrast to the contribution of other genes associated with MMFSI since it was first described in 1995.[7] Eight patients with MMFSI have been reported with mutations in SCN2A[18 19] and three with missense mutations in SCN1A.[20–22] Recessive mutations in TBC1D24, SLC25A22 and SLC12A5 have been described in four familial cases of MMFSI[23–25] and four patients have been described with copy number mutations.[20 26–28]

KCNT1 MUTATIONS IN ADNFLE

ADNFLE is a form of focal epilepsy in which patients experience violent motor seizures arising from sleep.[29] The disorder has previously been associated with mutations in three nicotinic acetylcholine receptor (nAChR) subunit genes.[30–33] Using

Figure 1 Diagram showing the KCNT1 protein structure and the positions of mutations identified in the gene to date. The KCNT1 protein consists of six hydrophobic transmembrane segments (S1–S6) with the pore-loop between S5 and S6. It has a large intracellular carboxy-terminal region containing tandem RCK domains and an NAD+ binding domain. The positions of missense mutations reported by previous studies are indicated, with different colours denoting different phenotypes. Mutations that are associated with more than one phenotype are marked with two or more colours. The numbers in bold type indicate the number of times recurrent mutations have been observed in multiple families and/or patients. ADNFLE, autosomal-dominant nocturnal frontal lobe epilepsy; EOEE, early-onset epileptic encephalopathy; MMFSI, malignant migrating focal seizures of infancy.

a strategy combining whole-genome linkage analysis and WES in a large family with ADNFLE, Heron and colleagues[5] identified a heterozygous missense mutation in *KCNT1*, p.Arg928Cys, which co-segregated with the epilepsy phenotype. Analysis of further patients identified *KCNT1* missense mutations in two additional families with ADNFLE and a patient with nocturnal frontal lobe epilepsy (NFLE), the sporadic form of ADNFLE (figure 1). Patients with ADNFLE and NFLE with *KCNT1* mutations were observed to have a more severe phenotype, which included an earlier age of seizure onset, a markedly increased frequency of refractory seizures and a high frequency of comorbid intellectual disability and psychiatric features compared with patients with ADNFLE with mutations in nAChR

subunit genes[5] (table 1). The majority of individuals with ADNFLE in two recent publications[12 14] also exhibited intellectual disability and psychiatric features, including depression, attempted suicide, anxiety and attention-deficit hyperactivity disorder. *KCNT1*-associated ADNFLE often presents as a severe form of ADNFLE with the comorbidities being key features of the disorder. This observation should guide genetic testing.

Subsequent studies of patients with ADNFLE or NFLE have identified additional *KCNT1* mutations and have shed some light on genotype–phenotype relationships. Møller and colleagues[14] described a sporadic case of NFLE with the same heterozygous mutation as the original family with ADNFLE, p.Arg928Cys,[5] highlighting that the same mutation may be seen

Table 1 Clinical features of patients with *KCNT1* mutations

Mutation	Associated phenotype(s)	Number of affected individuals	Mean age of seizure onset (range)	Comorbidities*	Reference
c.769C>G; p.His257Asp	MMFSI	1	2 weeks		14
c.785G>A; p.Arg262Gln	MMFSI	1	8 weeks		14
c.808C>G; p.Gln270Glu	MMFSI	1	2 days		15
c.811G>T; p.Val271Phe	MMFSI	1	2 weeks		10
c.862G>A; p.Gly288Ser	ADNFLE	1	3 years	Refractory seizures, ID	12
	MMFSI	6	2.4 months (5 weeks to 4 months)		9,14,15
	Leukodystrophy	1	2 months	ID, flaccid paraplegia	36
c.1018G>A; p.Val340Met	Multifocal epilepsy	1	3 years	Behavioural problems and learning difficulties, psychiatric features at seizure onset	14
c.1193G>A; p.Arg398Gln	ADNFLE	7 (2 families)	4.6 years (6 months to −18 years)	ID in 1, psychiatric disorders in 2	5,14
	MMFSI	3	2.8 months (10 days to −5 months)		12,14
c.1225C>T; p.Pro409Ser	MMFSI	1	2 months		15
c.1283G>A; p.Arg428Gln	MMFSI	5	1 months (0 days to 2.3 months)		6,11,14
	EOEE (unspecified)	1	1 months		15
c.1420C>T; p.Arg474Cys	MMFSI	2	4.5 days (0–9 days)		13,15
c.1421G>A; p.Arg474His	MMFSI	3	20 days (2 weeks to 1 months)		6,15
	West Syndrome	1	2 months		15
c.1429G>A; p.Ala477Thr	MMFSI	1	1–2 weeks		15
c.1887G>C: p.Lys629Asn	MMFSI	1	Neonatal		16
c.2280C>G; p.Ile760Met	MMFSI	1	3 days		6
c.2386T>C; p.Tyr796His	ADNFLE	4 (1 family)	5.5 years (3–8 years)	Refractory seizures in 2, ID in 3, psychiatric disorders in 2	5
	Focal seizures with secondary generalisation	1	18 m	Refractory seizures, developmental regression	16
c.2688G>A; p.Met896Ile	NFLE	1	9 years	Refractory seizures, psychiatric disorder	5
c.2718G>T; p.Gln906His	Leukodystrophy	1	3 months	ID, spastic quadriplegia, opsoclonus, nystagmus	36
c.2771C>T; p.Pro924Leu	MMFSI	2	1.3 months (1–1.5 months)	Cortical visual impairment in 1	8,15
c.2782C>T; p.Arg928Cys	ADNFLE/NFLE	12 (2 families, 1 sporadic)	5.9 (1–15 years)	Refractory seizures in 5, ID in 8, psychiatric disorders in 8, cardiac arrhythmia in 1	5,14
c.2794T>A; p.Phe932Ile	Leukoencephalopathy	1	1 months	Refractory seizures, developmental stagnation	35
c.2800G>A; p.Ala934Thr	MMFSI	5	1 months (4 days to 2.5 months)		6,10,12,14,15
c.2849G>A; p.Arg950Gln	MMFSI	1	5 months		14
c.2896G>A; p.Ala966Thr†	Ohtahara syndrome	1	1 days		34
c.3317G>A; p.Arg1106Gln	Brugada syndrome	1	NR		44

*Comorbidities of refractory seizures and developmental delay are present in all patients with EOEEs.
†Homozygous mutation.
ADNFLE, autosomal-dominant nocturnal frontal lobe of epilepsy; EOEE, early infantile epileptic encephalopathy; ID, intellectual disability; MMFSI, malignant migrating focal seizure of infancy; NFLE, nocturnal frontal lobe epilepsy; NR, not reported.

in a familial or sporadic setting. A family with five individuals affected with either nocturnal focal epilepsy or MMFSI was found to have a heterozygous *KCNT1* mutation, p.Arg398Gln.[14] This mutation was previously seen in a family with ADNFLE.[5] Similarly, Kim and colleagues[12] identified a patient with ADNFLE with a heterozygous missense *KCNT1* mutation p.Gly288Ser, and the same mutation has been reported in several unrelated patients with MMFSI.[9 14 15] These findings are important as they demonstrate that the same *KCNT1* mutation can give rise to either NFLE or MMFSI, even in members of the same family. The first reports of *KCNT1* mutations[5 6] gave rise to the idea that some mutations would cause ADNFLE while others would be responsible for MMFSI as different mutations were associated with each phenotype in

these studies. More recent data, however, show this is not the case and it is now clear that genotype–phenotype correlations with *KCNT1* mutations are not straightforward. While the identification of a *KCNT1* mutation will aid in diagnosis and counselling of patients, providing a prognosis based on a molecular result is likely to remain challenging.

KCNT1 MUTATIONS IN OTHER SEIZURE DISORDERS

The identification of *KCNT1* mutations in both ADNFLE and MMFSI, which are phenotypically distinct epileptic disorders, suggested that the two phenotypes may be part of a larger spectrum of epilepsies associated with mutations in the gene. This appears to be the case as *KCNT1* mutations have subsequently been identified in patients with other forms of EOEE, focal epilepsy and leukoencephalopathies (figure 1 and table 1). In a Japanese cohort of 362 patients with EOEEs, a patient with West Syndrome and a patient with an unclassified EOEE were found to have de novo heterozygous *KCNT1* mutations.[15] An individual with Ohtahara syndrome was found to have a *KCNT1* missense mutation, which was homozygous due to paternal isodisomy.[34] Each of the three patients with EOEE showed severe drug-resistant epilepsy and developmental delay, similar to that of the MMFSI phenotype (table 1), and two showed delayed myelination. The range of focal epilepsy phenotypes associated with *KCNT1* mutations was further expanded by the discovery of a heterozygous *KCNT1* mutation p. Val340Met in a patient with multifocal epilepsy[14] (figure 1 and table 1) and the identification of the p.Tyr796His mutation, previously reported in a family with ADNFLE, in a patient with severe nocturnal focal seizures with secondary generalisation and developmental regression.[16] Heterozygous de novo *KCNT1* mutations were identified using WES in a leukoencephalopathy patient with severe delayed myelination and refractory seizures[35] and in two patients with hypomyelinating leukodystrophy, whose initial symptom was seizures in both cases.[36] One of these was a novel mutation while the other was previously observed in both MMFSI and ADNFLE patients (p.Gly288Ser). These findings further demonstrate that *KCNT1* mutations are highly pleiotropic and can cause a wide spectrum of seizure disorders.

Pleiotropy is often observed with genes associated with epilepsy. Other examples include mutations in *SCN1A*,[37] *KCNQ2*[38] and *GABRG2*,[39] which can cause both mild and severe epilepsy phenotypes. Several epilepsy genes are also associated with non-epileptic phenotypes. For example, mutations in *PRRT2* can cause infantile epilepsy and/or paroxysmal movement disorders[40] while mutations in *TBC1D24* cause several forms of epilepsy and hearing loss as well as DOORS syndrome.[41] In some cases, the pleiotropy results from the differing functional effects of particular mutations. In other cases, such as *KCNT1*, this explanation is unlikely as the same mutation is associated with different phenotypes, sometimes within one family. In these cases, the variation in phenotype is likely to be due to modifier genes, environmental effects or a combination of both.

KCNT1 MUTATIONAL SPECTRUM AND PENETRANCE

Adding to the variability in the phenotypic expression of *KCNT1* mutations is incomplete penetrance. It originally appeared that *KCNT1* mutations show 100% penetrance, invariably causing severe disease.[5] [6] More recent findings, however, indicate that this is not the case. One individual in a family with ADNFLE with a *KCNT1* mutation did not have seizures and another individual from the same family was mildly affected,

experiencing a single seizure.[14] The father of the patient with Ohtahara syndrome described above, who was heterozygous for the mutation, was similarly unaffected.[34]

As mentioned above, parental somatic mosaicism of *KCNT1* mutations has been demonstrated in two cases. A Japanese patient[15] with the p.Pro924Leu mutation and an Australian patient[14] with the p.Ala934Thr mutation inherited the mutations from their unaffected mothers who were confirmed to be somatic mosaic for the respective mutations. The levels of mosaicism were determined to be between 14% and 29% in samples of blood, saliva and nails from the mother of the Japanese patient[15] and approximately 60% in blood in the mother of the Australian patient.[14] These observations show that high levels of somatic mosaicism of *KCNT1* mutations can exist without causing detectable seizure phenotypes.

Of the 24 different *KCNT1* mutations described to date, nine have now been observed multiple (up to eight) times (figure 1). This suggests that mutational 'hot-spots' play a role in *KCNT1*-mediated pathogenesis. Seven of these recurrent mutations occur in CpG dinucleotides and are C>T or G>A changes. CpG dinucleotides are known to be sites of recurrent mutation due to the spontaneous deamination of 5-methylcytosine to thymine, resulting in G:T mismatches. The inaccurate repair of these results in mutation.[42] [43]

The data reported to date show that there is considerable phenotypic variability and incomplete penetrance associated with *KCNT1* mutations, with phenotypes ranging from individuals who are apparently unaffected, to ADNFLE, to devastating disorders such as MMFSI or other EOEEs. This cannot be attributed solely to differences in the effects stemming from the different amino acid alterations as phenotypic variability is seen associated with the same mutation even within genetically similar individuals within single families. Uncovering the biological basis of this variation in phenotype will improve our understanding of KCNT1 channel biology and our ability to diagnose and give accurate prognoses for patients with *KCNT1* mutations.

KCNT1 MUTATIONS AND POSSIBLE LINKS WITH CARDIAC DISORDERS

A targeted resequencing study examining ion channel mutations in patients with the cardiac arrhythmia Brugada syndrome (Brs) identified a de novo heterozygous missense *KCNT1* mutation, p. Arg1106Gln in one individual.[44] The patient with Brs with the *KCNT1* mutation was reported to have seizures, consistent with previous findings. Furthermore, one of the patients with ADNFLE in a family with a *KCNT1* mutation reported by Møller and colleagues[14] has cardiac arrhythmia with features resembling Brs, suggesting that there may be a link between perturbation of KCNT1 protein function and cardiac arrhythmias. Another member of the same family died due to sudden unexpected death in epilepsy (SUDEP), thought to be associated with cardiac dysfunction.[14] These observations and the expression of *KCNT1* in the heart[1] [45] may suggest involvement of *KCNT1* in heart function, possibly in the regulation of action potentials similar to its role in the brain.

The possible association of *KCNT1* mutations with cardiac disorders is part of an increasing body of evidence that both epilepsy and cardiac disorders can result from the same channelopathy. It is feasible that dysfunctional ion channels expressed in the brain and heart lead to the dysregulation of action potentials, contributing to both seizure activity and cardiac arrhythmia. Mutations in two known cardiac arrhythmia genes, *SCN5A* and *KCNH2*, have previously been found in patients with

epilepsy. *SCN5A* mutations have been found in a patient with idiopathic epilepsy who died due to SUDEP,[46] a family with Brs and epilepsy,[47] and in a patient with neonatal seizures and long QT syndrome (LQTS).[48] An increased frequency of seizure disorders was observed in patients with LQTS caused by mutations in *KCNH2*[49] and a *KCNH2* mutation was found in a patient with a history of epilepsy who was undergoing cardiologic evaluation.[50] These findings suggest that the association between genetic epilepsies and cardiac arrhythmias may be more significant than has previously been appreciated. The observation of cardiac disorders in patients with *KCNT1* mutations and seizure disorders further supports the association of epileptic and cardiac channelopathies, and further studies are needed to shed light on the biology of this possible link.

STRUCTURE, EXPRESSION AND FUNCTION OF *KCNT1* AND ITS PROTEIN PRODUCT

The human *KCNT1* gene is located at chromosome 9q34.3 and comprises 31 exons. The gene is transcribed to produce a 4.7 kb mRNA that encodes a 138 kDa protein. Expression profiling of the human mRNA showed high expression in most brain regions, except the corpus callosum and substantia nigra.[1]

The full-length human KCNT1 protein contains 1235 amino acid residues and is the largest potassium channel subunit identified. It shares 76% amino acid identity (protein alignment: http://blast.ncbi.nlm.nih.gov) with and has been shown to interact with the KCNT2 protein (also known as SLICK),[51] the only other protein in the sodium-activated K^+ channel family.[3] The KCNT1 protein comprises a small intracellular amino-terminal domain, six hydrophobic transmembrane segments (S1–S6) with a pore-loop between S5 and S6, and a large intracellular carboxy-terminal domain.[3 52] The C-terminal domain contains tandem regulators of K^+ conductance (RCK) domains and an NAD+ binding domain.[3 53] The KCNT1 and KCNT2 subunits are thought to form a tetrameric channel[51] that mediates a sodium-sensitive potassium current that is found in a range of neuronal cells.[54–62] Its action of restoring polarisation after repetitive neuronal firing assists with the regulation of neuronal firing.[63]

The interaction of the KCNT1 and KCNT2 channel subunits raises the possibility that mutations in *KCNT2* could cause similar phenotypes to those in *KCNT1*. However, no such mutations have been described in multiple exome sequencing studies of patients with epileptic encephalopathies.[8 34 64–67] This strongly suggests that *KCNT2* mutations do not cause epileptic encephalopathies with the same frequency as *KCNT1* mutations. This may be because the expression patterns of the two genes do not completely overlap, suggesting some differences in their function. Differences in expression patterns of the two genes have been described in rodents.[68 69] Data from the Allen Brain Atlas (http://human.brain-map.org) indicate that differing expression patterns of the two genes also occur in humans.

Two human *KCNT1* transcripts have been identified to date (NCBI data: http://www.ncbi.nlm.nih.gov/gene/57582). In rodents, five distinct *Kcnt1* transcripts have been identified empirically.[4] These transcripts differ only at the 5′ end, producing subunits with differing N-terminal domains, but identical transmembrane and C-terminal domains. Two of the rodent transcripts are termed Slack-A and Slack-B. Studies in mouse and rat showed that these transcripts have differing expression patterns in the brain and produce proteins with different electrophysiological properties.[4 52 70 71] Slack-A is rapidly activated following depolarisation while Slack-B has slower activation kinetics.[4] Slack-A appears to have widespread expression while expression of Slack-B is restricted to the frontal cortex and some non-cortical regions.[4 52 71]

All studies of human *KCNT1* thus far have focused on splice isoform 1 (NM_020822.2), which is partially orthologous to rodent Slack-A, but codes for a protein with additional sequence at the N-terminal end (figure 2). The expression of the transcripts orthologous to Slack-A and Slack-B in humans has not been empirically demonstrated; however, alignments of rat Slack-A and Slack-B protein to the *KCNT1* genomic sequence in the Ensembl Genome Browser (http://www.ensembl.org) show that sequences homologous to the first and second exons specific for both Slack-A and Slack-B are present within the human *KCNT1* gene (figure 2). It is, therefore, possible that the same isoforms with the same expression patterns exist in both humans and rodents.

Taken together, these studies show that *KCNT1* is highly expressed in the brain. The gene in rodents appears to have several differentially expressed isoforms with different functional properties. The functional roles of these isoforms are not yet understood and their existence has not been empirically demonstrated in humans. Further study of the physiology and expression of the different isoforms is required before we can have a complete understanding of the differential forms of *KCNT1* transcripts and the proteins they encode.

EFFECTS OF *KCNT1* MUTATIONS ON CHANNEL FUNCTION

The 24 seizure disorder-related *KCNT1* mutations described to date are all missense mutations, with no nonsense or other truncating mutations having been identified. This suggests that perturbation of normal KCNT1 protein function, rather than the loss of its function, underlies the pathogenic mechanism that leads to the observed phenotypes. This may be consistent with the phenotypes observed in a *Kcnt1* null mouse model,[70] which shows slightly reduced locomotive activity and impaired reverse learning memory and adaptation to new environments, but no seizures. Animal models based on *KCNT1* mutations observed in human patients will be required in order to accurately analyse the mechanism of these disease-causing mutations.

The positions of *KCNT1* mutations associated with seizure disorders show clustering in particular functional domains of the KCNT1 protein. Specifically, they alter amino acid residues located near to or within the S5 and S6 transmembrane segments, the RCK domains or the NAD+ binding domain (figure 1). The sole exception is the mutation seen in the patient with Brs, p.Arg1106Gln, which is located closer to the C-terminus and is not in a characterised functional domain. The S5 and S6 segments flank the pore loop of the channel, while both the RCK domain and the NAD+ binding domain allosterically regulate channel opening and potassium ion permeation.[72–74] This suggests that most of the mutations found have the potential to alter channel opening.

In vitro functional studies using either the rat Slack-B variant[6 12 34] or the human *KCNT1* transcript 1[16 75] expressed in *Xenopus* oocytes (frog eggs) have shown that the *KCNT1* mutations found in individuals with ADNFLE, MMFSI and Ohtahara syndrome result in an increase in current amplitude of between 3-fold and 22-fold compared with wild-type, indicating a hypermorphic mutational effect. Studies performed[6 12 16 34 75] to characterise the electrophysiological effects of KCNT1 mutations have produced variable results in terms of the extent of increase in the current amplitude that is associated with particular mutations, and further characterisation is required. Additionally, patch-clamping experiments carried out in *Xenopus* oocytes demonstrated that channel cooperativity, that

```
Human Isoform 1    MPLPDGARTPGGVCREARGGGYTNRTFEFDDGQCAPRRPCAGDGALLDTAGFKMSDLDSEVLPPPRYRFRDLLLGDPSFQNDDR
Human Slack A      ...................................................MSDLDSEVLPPPRYRFRDLLLGDPSFQNDDR
Rat Slack A        ...................................................MNDLDTEVLPPPRYRFRDLLLGDQTFPNDDR
Mouse Slack A      ...................................................MNDLDTEVLPPPRYRFRDLLLGDQPFPNDDR
Human Slack B      .....................................................................................
Rat Slack B        .....................................................................................
Mouse Slack B      .....................................................................................


Human Isoform 1    ..............................................VQVEFYVNENTFKERLKLFF
Human Slack A      ..............................................LPVEDFSLDSSLSQVQVEFYVNENTFKERLKLFF
Rat Slack A        ..............................................VQVEFYVNENTFKERLKLFF
Mouse Slack A      ..............................................LHVEDFSLDSSLSQVQVEFYVNENTFKERLKLFF
Human Slack B      MARAKLPRSPSEGKAGPGGAPAGAAAPEEPHGLSPLLPARGGGSVGSDVGQRLPVEDFSLDSSLSQVQVEFYVNENTFKERLKLFF
Rat Slack B        MARAKLPRSPSEGKAGPGDTPAGSAAPEEPHGLSPLLPTRGGGSVGSDVGQRLHVEDFSLDSSLSQVQVEFYVNENTFKERLKLFF
Mouse Slack B      MARAKLPRSPSEGKAGPGDTPAGSAAPEEPHGLSPLLPTRGGGSVGSDVGQRLHVEDFSLDSSLSQVQVEFYVNENTFKERLKLFF
```

Figure 2 Amino acid alignment for KCNT1 isoforms in human, rat and mouse. Amino acid sequences from the first and second exons of human KCNT1 isoform 1 (NM020822.2) were aligned to mouse and rat Slack-A and Slack-B isoforms previously reported by Brown et al.[4] Amino acid sequences for the hypothetical human SLACK-A and human SLACK-B isoforms were derived from ENST00000486577 and ENST00000490355 respectively from the Ensembl Genome Browser.

is, an increase in the time channels remain open for and the number of simultaneous channel openings, occurs when multiple (four or more) KCNT1 channels are present in the same patch.[12] Cooperativity was increased in mutant channels, leading to a larger increase in channel current compared with wild-type than is seen with single channels. This cooperativity may also occur in vivo where channels are clustered in specific regions of neurons. Therefore, it is possible that studies done in whole *Xenopus* oocytes, as opposed to patch-clamping experiments, do not give a complete picture of the functional effects of endogenous *KCNT1* mutations in neurons, as cooperativity is not observed in these experiments.

The KCNT1 channel subunit is involved in the slow hyperpolarisation after a single action potential or following repetitive firing of action potentials (figure 3).[3] It has been speculated that in patients with *KCNT1* mutations, enhanced potassium current in inhibitory interneurons leads to prolonged hyperpolarisation, resulting in an imbalance between neuronal excitation and inhibition that lead to seizures.[12 75] The differing electrophysiological properties of the different KCNT1 isoforms may play a role in the expression of the different phenotypes caused by *KCNT1* mutations. The disruption of the KCNT1 Slack-B-orthologue function may be the major cause of seizures in patients with ADNFLE, given its expression in the frontal cortex and its slow activation property that could facilitate the rhythmic firing of neurons[4 71] that is likely to be required for the oscillatory currents observed during sleep (sleep spindles).[76] Hypermorphic mutations in *KCNT1* could lead to seizures in both MMSFI and ADNFLE due to an increase in Slack-A-orthologue function. Since Slack-A is rapidly activated following depolarisation,[4] an increase in Slack-A current could lead to a more rapid membrane repolarisation, allowing faster repriming of sodium channels in excitatory neurons, resulting in a higher firing rate of action potentials throughout the brain. Additionally, it is possible that patients with MMFSI have ADNFLE-type seizures that are not observed due to the severity of neurological disease in MMFSI.

KCNT1 mutations may have effects additional to the demonstrated increase in potassium current. The C-terminal domain of the KCNT1 protein is known to interact with the Fragile X mental retardation protein (FMRP).[77] Alterations in this interaction may be related to the comorbidities seen in patients with *KCNT1* mutations. For example, it is possible that the high incidence of intellectual disability seen in patients with ADNFLE with *KCNT1* mutations[5 12 14] is due to altered interaction of the KCNT1 channel with FMRP.

Figure 3 Illustration of a general model of an action potential. As the membrane potential reaches threshold potential, voltage-gated sodium channels (eg, SCN1A) open, allowing sodium ions to flow into the cell. The membrane potential increases, and this stage is known as depolarisation. When membrane potential reaches +30 mV, sodium channels closes and potassium channels such as voltage-gated potassium channels (eg, KCNA1), voltage and calcium-sensitive potassium channels (eg, KCNMA1) and sodium-activated potassium channels (eg, KCNT1) begin to open, allowing the flow of potassium ions from the cell. With the potassium channels open, the membrane begins to repolarise back towards its resting potential. The closure for certain potassium channels such as KCNT1 is a delayed process, causing the membrane potential to fall below −70 mV, which is known as hyperpolarisation. The Na⁺/K⁺ pump restores the membrane potential from hyperpolarisation back to its resting potential. Figure adapted and modified from Bean.[81]

TARGETING *KCNT1* MUTATIONS WITH QUINIDINE
The identification of *KCNT1* mutations as a genetic cause for MMFSI and ADNFLE suggests that these conditions may be treatable using a drug that specifically targets the KCNT1 channel. One such drug, quinidine, has recently garnered much interest. Quinidine is an inhibitor of several types of potassium channels, including KCNT1,[78 79] and is currently used as an antiarrhythmic agent and antimalarial drug.[80] Since functional studies have shown that mutations in *KCNT1* cause an increase

in the channel current,[6 12 16 34 75] using an inhibitor to reverse this abnormal channel function could treat seizures in patients with hypermorphic mutations in *KCNT1*. Indeed, the effectiveness of quinidine in reversing the increased current of mutant KCNT1 channels has been demonstrated in vitro.[16 75]

Quinidine treatment has been trialled in three patients with *KCNT1* mutations for whom treatment with standard antiepileptic therapies had been unsuccessful.[11 16] Two patients with MMFSI showed marked improvement in seizure control following quinidine administration. One was seizure-free for 4 months at the time the trial was reported[11] while the other had an 80% reduction in seizure frequency.[16] Both patients' developmental progress was improved, although the patient reported by Bearden and colleagues[11] remained severely developmentally delayed, which was thought to be due either to irreversible brain damage caused by frequent seizures prior to quinidine dosing or developmental effects of the mutant KCNT1 protein, particularly its interaction with FMRP.[77] The extent of improvement in the second patient's developmental progress was not described.[16] The third patient, who had an unusual phenotype of nocturnal focal seizures with secondary generalisation and developmental regression, showed no significant improvement with quinidine treatment.[16] The success of quinidine as an epilepsy treatment in two of three patients is encouraging for *KCNT1* mutation-positive patients, who often have seizures resistant to multiple antiepileptic drugs. However, caution must be exercised when using quinidine as it acts on multiple potassium channels including those in the heart and could possibly cause a long QT interval and lead to cardiac arrest.[11] As discussed above, cardiac arrhythmias were reported in a patient with ADNFLE and also in a patient with Brs carrying *KCNT1* mutations, raising the possibility that undiagnosed cardiac disorders exist in patients with *KCNT1* mutations.[14 44] Hence, the required trials of quinidine in larger cohorts of patients with *KCNT1* mutations should include ECG monitoring to examine potential cardiac side effects. Development of a specific KCNT1 channel-targeting inhibitor with good blood–brain barrier penetration may provide a safer and more effective alternative to quinidine.

SUMMARY

Since the first report of mutations in *KCNT1* by two groups in patients with epilepsy in 2012,[5 6] a number of studies have confirmed the importance of the gene in human neurological disorders.[8–16 34–36] Mutations in *KCNT1* appear to cause a wide spectrum of seizure disorders, which include ADNFLE, multifocal epilepsy, MMFSI, Ohtahara syndrome and leukoencephalopathies. Moreover, *KCNT1* mutations are being considered in disorders beyond neurological phenotypes and may be associated with Brs[44] and other cardiac arrhythmias.[14] Further studies are now required to understand the underlying biology of *KCNT1*-related disorders. This will improve the treatment of patients with *KCNT1* mutations by enabling the use of therapies that target the specific biological pathways they affect. Indeed, work towards personalised medicine based on molecular genetic data has already begun with the trial of quinidine to treat patients with *KCNT1* mutations.

REFERENCES

1 Nagase T, Kikuno R, Ishikawa K, Hirosawa M, Ohara O. Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. *DNA Res* 2000;7:65–73.

2 Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. *Pharmacol Rev* 2005;57:463–72.

3 Bhattacharjee A, Kaczmarek LK. For K+ channels, Na+ is the new Ca2+. *Trends Neurosci* 2005;28:422–8.

4 Brown MR, Kronengold J, Gazula V-R, Spilianakis GC, Flavell RA, von Hehn CAA, Bhattacharjee A, Kaczmarek LK. Amino-termini isoforms of the Slack K+ channel, regulated by alternative promoters, differentially modulate rhythmic firing and adaptation. *J Physiol* 2008;586:5161–79.

5 Heron SE, Smith KR, Bahlo M, Nobili L, Kahana E, Licchetta L, Oliver KL, Mazarib A, Afawi Z, Korczyn A, Plazzi G, Petrou S, Berkovic SF, Scheffer IE, Dibbens LM. Missense mutations in the sodium-gated potassium channel gene *KCNT1* cause severe autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 2012;44:1188–90.

6 Barcia G, Fleming MR, Deligniere A, Gazula V-R, Brown MR, Langouet M, Chen H, Kronengold J, Abhyankar A, Cilio R, Nitschke P, Kaminska A, Boddaert N, Casanova J-L, Desguerre I, Munnich A, Dulac O, Kaczmarek LK, Colleaux L, Nabbout R. De novo gain-of-function *KCNT1* channel mutations cause malignant migrating partial seizures of infancy. *Nat Genet* 2012;44:1255–9.

7 Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating Partial Seizures in Infancy: A Malignant Disorder with Developmental Arrest. *Epilepsia* 1995;36:1017–24.

8 Epi4K Consortium & Epilepsy Phenome/Genome Project Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, Glauser T, Goldstein DB, Han Y, Heinzen EL, Hitomi Y, Howell KB, Johnson MR, Kuzniecky R, Lowenstein DH, Lu YF, Madou MR, Marson AG, Mefford HC, Esmaeeli Nieh S, O'Brien TJ, Ottman R, Petrovski S, Poduri A, Ruzzo EK, Scheffer IE, Sherr EH, Yuskaitis CJ, Abou-Khalil B, Alldredge BK, Bautista JF, Berkovic SF, Boro A, Cascino GD, Consalvo D, Crumrine P, Devinsky O, Dlugos D, Epstein MP, Fiol M, Fountain NB, French J, Friedman D, Geller EB, Glauser T, Glynn S, Haut SR, Hayward J, Helmers SL, Joshi S, Kanner A, Kirsch HE, Knowlton RC, Kossoff EH, Kuperman R, Kuzniecky R, Lowenstein DH, McGuire SM, Motika PV, Novotny EJ, Ottman R, Paolicchi JM, Parent JM, Park K, Poduri A, Scheffer IE, Shellhaas RA, Sherr EH, Shih JJ, Singh R, Sirven J, Smith MC, Sullivan J, Lin Thio L, Venkat A, Vining EPG, Von Allmen GK, Weisenberg JL, Widdess-Walsh P, Winawer MR. De novo mutations in epileptic encephalopathies. *Nature* 2013;501:217–21.

9 Ishii A, Shioda M, Okumura A, Kidokoro H, Sakauchi M, Shimada S, Shimizu T, Osawa M, Hirose S, Yamamoto T. A recurrent *KCNT1* mutation in two sporadic cases with malignant migrating partial seizures in infancy. *Gene* 2013;531:467–71.

10 McTague A, Appleton R, Avula S, Cross JH, King MD, Jacques TS, Bhate S, Cronin A, Curran A, Desurkar A, Farrell MA, Hughes E, Jefferson R, Lascelles K, Livingston J, Meyer E, McLellan A, Poduri A, Scheffer IE, Spinty S, Kurian MA, Kneen R. Migrating partial seizures of infancy: Expansion of the electroclinical, radiological and pathological disease spectrum. *Brain* 2013;136:1578–91.

11 Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D, Goldberg EM. Targeted treatment of migrating partial seizures of infancy with quinidine. *Ann Neurol* 2014;76:457–61.

12 Kim GE, Kronengold J, Barcia G, Quraishi IH, Martin HC, Blair E, Taylor JC, Dulac O, Colleaux L, Nabbout R, Kaczmarek LK. Human Slack Potassium Channel Mutations Increase Positive Cooperativity between Individual Channels. *Cell Rep* 2014;9:1661–72.

13 Shimada S, Hirano Y, Ito S, Oguni H, Nagata S, Shimojima K, Yamamoto T. A novel KCNT1 mutation in a Japanese patient with epilepsy of infancy with migrating focal seizures. *Hum Genome Var* 2014;1:14027.

14 Møller RS, Heron SE, Larsen LHG, Lim CX, Ricos MG, Bayly MA, van Kempen MJA, Klinkenberg S, Andrews I, Kelley K, Ronen GM, Callen D, McMahon JM, Yendle SC, Carvill GL, Mefford HC, Nabbout R, Poduri A, Striano P, Baglietto MG, Zara F, Smith NJ, Pridmore C, Gardella E, Nikanorova M, Dahl HA, Gellert P, Scheffer IE, Gunning B, Kragh-Olsen B, Dibbens LM. Mutations in KCNT1 cause a spectrum of focal epilepsies. *Epilepsia* 2015;56:e114–20.

15 Ohba C, Kato M, Takahashi N, Osaka H, Shiihara T, Tohyama J, Nabatame S, Azuma J, Fujii Y, Hara M, Tsurusawa R, Inoue T, Ogata R, Watanabe Y, Togashi N, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Tanaka F, Saitsu H, Matsumoto N. De novo KCNT1 mutations in early-onset epileptic encephalopathy. *Epilepsia* 2015;56:e121–8.

16 Mikati MA, Jiang Y, Carboni M, Shashi V, Petrovski S, Spillmann R, Milligan CJ, Li M, Grefe A, McConkie A, Berkovic S, Scheffer I, Mullen S, Bonner M, Petrou S, Goldstein D. Quinidine in the Treatment of KCNT1-Positive Epilepsies. *Ann Neurol* 2015;78:995–9.

17 De Filippo MR, Rizzo F, Marchese G, Giurato G, Nassa G, Ravo M, Tarallo R, Pironti E, Vecchi M, Crichiutti G, Capizzi G, Verrotti A, Weisz A, Coppola G. Lack of pathogenic mutations in six patients with MMPSI. *Epilepsy Res* 2014;108:340–4.

18 Dhamija R, Wirrell E, Falcao G, Kirmani S, Wong-Kisiel LC. Novel de novo SCN2A mutation in a child with migrating focal seizures of infancy. *Pediatr Neurol* 2013;49:486–8.

19 Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez-Casero V, Webster R, Clark D, Freeman JL, Calvert S, Olson HE, Mandelstam S, Poduri A, Mefford HC, Harvey AS, Scheffer IE. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. *Neurology* 2015;85:958–66.

20 Carranza Rojo D, Hamiwka L, McMahon JM, Dibbens LM, Arsov T, Suls A, Stödberg T, Kelley K, Wirrel E, Appleton B, Mackay M, Freeman JL, Yendle SC, Berkovic SF, Bienvenu T, De Jonghe P, Thorburn D, Mulley JC, Mefford HC, Scheffer IE. De novo SCN1A mutations in migrating partial seizures of infancy. *Neurology* 2011;77:380–3.

21 Freilich ER, Jones JM, Gaillard WD, Conry JA, Tsuchida TN, Reyes C, Dib-Hajj S Waxman SG, Meisler MH, Pearl PL. Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy. *Arch Neurol* 2011;68:665–71.

22 Shein SL, Reynolds TQ, Gedela S, Kochanek PM, Bell MJ. Therapeutic hypothermia for refractory status epilepticus in a child with malignant migrating partial seizures of infancy and SCN1A mutation: a case report. *Ther Hypothermia Temp Manag* 2012;2:144–9.

23 Milh M, Falace A, Villeneuve N, Vanni N, Cacciagli P, Assereto S, Nabbout R, Benfenati F, Zara F, Chabrol B, Villard L, Fassio A. Novel Compound Heterozygous Mutations in *TBC1D24* Cause Familial Malignant Migrating Partial Seizures of Infancy. *Hum Mutat* 2013;34:869–72.

24 Poduri A, Heinzen EL, Chitsazzadeh V, Lasorsa FM, Elhosary C, LaCoursiere CM, Martin E, Yuskaitis CJ, Hill RS, Atabay KD, Barry B, Partlow JN, Bashiri FA, Zeidan RM, Elmalik SA, Kabiraj MMU, Kothare S, Stödberg T, Scheffer IE, Barkovich AJ, Palmieri F, Salih M, Walsh CA. *SLC25A22* is a novel gene for migrating partial seizures in infancy. *Ann Neurol* 2013;74:873–82.

25 Stödberg T, McTague A, Ruiz AJ, Hirata H, Zhen J, Long P, Farabella I, Meyer E, Kawahara A, Vassallo G, Stivaros SM, Bjursell MK, Stranneheim H, Tigerschiöld S, Persson B, Bangash I, Das K, Hughes D, Lesko N, Lundeberg J, Scott RC, Poduri A, Scheffer IE, Smith H, Gissen P, Schorge S, Reith MEA, Topf M, Kullmann DM, Harvey RJ, Wedell A, Kurian MA. Mutations in *SLC12A5* in epilepsy of infancy with migrating focal seizures. *Nat Commun* 2015;6:8038.

26 Bedoyan JK, Kumar RA, Sudi J, Silverstein F, Ackley T, Iyer RK, Christian SL, Martin DM. Duplication 16p11.2 in a child with infantile seizure disorder. *Am J Med Genet Part A* 2010;152:1567–74.

27 Poduri A, Chopra SS, Neilan EG, Elhosary PC, Kurian MA, Meyer E, Barry BJ, Khwaja OS, Salih MAM, Stödberg T, Scheffer IE, Maher ER, Sahin M, Wu B-L, Berry GT, Walsh CA, Picker J, Kothare SV. Homozygous *PLCB1* deletion associated with malignant migrating partial seizures in infancy. *Epilepsia* 2012;53:e146–50.

28 Kodera H, Kato M, Nord AS, Walsh T, Lee M, Yamanaka G, Tohyama J, Nakamura K, Nakagawa E, Ikeda T, Ben-Zeev B, Lev D, Lerman-Sagie T, Straussberg R, Tanabe S, Ueda K, Amamoto M, Ohta S, Nonoda Y, Nishiyama K, Tsurusaki Y, Nakashima M, Miyake N, Hayasaka K, King M-C, Matsumoto N, Saitsu H. Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy. *Epilepsia* 2013;54:1262–9.

29 Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann E, Andermann F, Desbiens R, Keene D, Cendes F, Manson JI, Constantinou JEC, McIntosh A, Berkovic SF. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. *Brain* 1995;118(Pt 1):61–73.

30 Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 1995;11:201–3.

31 De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, Ballabio A, Wanke E, Casari G. The nicotinic receptor β2 subunit is mutant in nocturnal frontal lobe epilepsy. *Nat Genet* 2000;26:275–6.

32 Phillips HA, Favre I, Kirkpatrick M, Zuberi SM, Goudie D, Heron SE, Scheffer IE, Sutherland GR, Berkovic SF, Bertrand D, Mulley JC. CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. *Am J Hum Genet* 2001;68:225–31.

33 Aridon P, Marini C, Di Resta C, Brilli E, De Fusco M, Politi F, Parrini E, Manfredi I, Pisano T, Pruna D, Curia G, Cianchetti C, Pasqualetti M, Becchetti A, Guerrini R, Casari G. Increased sensitivity of the neuronal nicotinic receptor α2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. *Am J Hum Genet* 2006;79:342–50.

34 Martin HC, Kim GE, Pagnamenta AT, Murakami Y, Carvill GL, Meyer E, Copley RR, Rimmer A, Barcia G, Fleming MR, Kronengold J, Brown MR, Hudspith KA, Broxholme J, Kanapin A, Cazier J-B, Kinoshita T, Nabbout R, The WGS500 Consortium, Bentley D, McVean G, Heavin S, Zaiwalla Z, McShane T, Mefford HC, Shears D, Stewart H, Kurian MA, Scheffer IE, Blair E, Donnelly P, Kaczmarek LK, Taylor JC. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. *Hum Mol Genet* 2014;23:3200–11.

35 Vanderver A, Simons C, Schmidt JL, Pearl PL, Bloom M, Lavenstein B, Miller D, Grimmond SM, Taft RJ. Identification of a novel de novo p.Phe932Ile KCNT1 mutation in a patient with leukoencephalopathy and severe epilepsy. *Pediatr Neurol* 2014;50:112–14.

36 Arai-Ichinoi N, Uematsu M, Sato R, Suzuki T, Kudo H, Kikuchi A, Hino-Fukuyo N, Matsumoto M, Igarashi K, Haginoya K, Kure S. Genetic heterogeneity in 26 infants with a hypomyelinating leukodystrophy. *Hum Genet* 2015. Published Online First: 23 November 2015.

37 Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A Mutations and Epilepsy. *Hum Mutat* 2005;25:535–42.

38 Bellini G, Micele F, Soldovieri MV, Miraglia del Giudice E, Coppola G, Taglialatela M. KCNQ2-Related disorders. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, eds. *GeneReviews® [Internet]*. Seattle, WA: University of Washington, Seattle; 1993–2015. 2010 (updated 11 Apr 2013).

39 Harkin LA, Bowser DN, Dibbens LM, Singh R, Phillips F, Wallace RH, Richards MC, Williams DA, Mulley JC, Berkovic SF, Scheffer IE, Petrou S. Truncation of the GABA$_A$-receptor γ2 subunit in a family with generalized epilepsy with febrile seizures plus. *Am J Hum Genet* 2002;70:530–6.

40 Heron SE, Dibbens LM. Role of PRRT2 in common paroxysmal neurological disorders: a gene with remarkable pleiotropy. *J Med Genet* 2013;50:133–9.

41 Mucha BE, Hennekam RCM, Sisodiya S, Campeau PM. TBC1D24-related disorders. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, eds. *GeneReviews® [Internet]*. Seattle, WA: University of Washington, Seattle; 1993–2015. 2015.

42 Holliday R, Grigg GW. DNA methylation and mutation. *Mutat Res* 1993;285:61–7.

43 Cooper DN, Mort M, Stenson PD, Ball EV, Chuzhanova NA. Methylation-mediated deamination of 5-methylcytosine appears to give rise to mutations causing human inherited disease in CpNpG trinucleotides, as well as in CpG dinucleotides. *Hum Genomics* 2010;4:406–10.

44 Juang J-MJ, Lu T-P, Lai L-C, Ho C-C, Liu Y-B, Tsai C-T, Lin L-Y, Yu C-C, Chen W-J, Chiang F-T, Yeh S-FS, Lai L-P, Chuang EY, Lin J-L. Disease-Targeted Sequencing of Ion Channel Genes identifies de novo mutations in Patients with Non-Familial Brugada Syndrome. *Sci Rep* 2014;4:6733.

45 Brawand D, Soumillon M, Necsulea A, Julien P, Csárdi G, Harrigan P, Weier M, Liechti A, Aximu-Petri A, Kircher M, Albert FW, Zeller U, Khaitovich P, Grützner F, Bergmann S, Nielsen R, Pääbo S, Kaessmann H. The evolution of gene expression levels in mammalian organs. *Nature* 2011;478:343–8.

46 Aurlien D, Leren TP, Taubøll E, Gjerstad L. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. *Seizure* 2009;18:158–60.

47 Parisi P, Oliva A, Coll Vidal M, Partemi S, Campuzano O, Iglesias A, Pisani D, Pascali VL, Paolino MC, Villa MP, Zara F, Tassinari CA, Striano P, Brugada R. Coexistence of epilepsy and Brugada syndrome in a family with SCN5A mutation. *Epilepsy Res* 2013;105:415–18.

48 Heron SE, Hernandez M, Edwards C, Edkins E, Jansen FE, Scheffer IE, Berkovic SF, Mulley JC. Neonatal seizures and long QT syndrome: a cardiocerebral channelopathy? *Epilepsia* 2010;51:293–6.

49 Johnson JN, Hofman N, Haglund CM, Cascino GD, Wilde AAM, Ackerman MJ. Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy. *Neurology* 2009;72:224–31.

50 Omichi C, Momose Y, Kitahara S. Congenital long QT syndrome presenting with a history of epilepsy: Misdiagnosis or relationship between channelopathies of the heart and brain? *Epilepsia* 2010;51:289–92.

51 Chen H, Kronengold J, Yan Y, Gazula V-R, Brown MR, Ma L, Ferreira G, Yang Y, Bhattacharjee A, Sigworth FJ, Salkoff L, Kaczmarek LK. The N-terminal domain of Slack determines the formation and trafficking of Slick/Slack heteromeric sodium-activated potassium channels. *J Neurosci* 2009;29:5654–65.

52 Joiner WJ, Tang MD, Wang LY, Dworetzky SI, Boissard CG, Gan L, Gribkoff VK, Kaczmarek LK. Formation of intermediate-conductance calcium-activated potassium channels by interaction of Slack and Slo subunits. *Nat Neurosci* 1998;1:462–9.

53 Tamsett TJ, Picchione KE, Bhattacharjee A. NAD$^+$ activates K$_{Na}$ channels in dorsal root ganglion neurons. *J Neurosci* 2009;29:5127–34.

54 Bader CR, Bernheim L, Bertrand D. Sodium-activated potassium current in cultured avian neurones. *Nature* 1985;317:540–2.

55 Hartung K. Potentiation of a transient outward current by Na$^+$ influx in crayfish neurones. *Pflügers Arch Eur J Physiol* 1985;404:41–4.

56 Dryer SE, Fujii JT, Martin AR. A Na$^+$-activated K$^+$ current in cultured brain stem neurones from chicks. *J Physiol* 1989;410:283–96.

57 Schwindt PC, Spain WJ, Crill WE. Long-lasting reduction of excitability by a sodium-dependent potassium current in cat neocortical neurons. *J Neurophysiol* 1989;61:233–44.

58 Haimann C, Bernheim L, Bertrand D, Bader CR. Potassium current activated by intracellular sodium in quail trigeminal ganglion neurons. *J Gen Physiol* 1990;95:961–79.

59 Saito M, Wu CF. Expression of ion channels and mutational effects in giant Drosophila neurons differentiated from cell division-arrested embryonic neuroblasts. *J Neurosci* 1991;11:2135–50.

60 Egan TM, Dagan D, Kupper J, Levitan IB. Properties and rundown of sodium-activated potassium channels in rat olfactory bulb neurons. *J Neurosci* 1992;12:1964–76.

61 Dale N. A large, sustained Na$^+$- and voltage-dependent K$^+$ current in spinal neurons of the frog embryo. *J Physiol* 1993;462:349–72.

62 Franceschetti S, Lavazza T, Curia G, Aracri P, Panzica F, Sancini G, Avanzini G, Magistretti J. Na$^+$-activated K$^+$ current contributes to postexcitatory hyperpolarization in neocortical intrinsically bursting neurons. *J Neurophysiol* 2003;89:2101–11.

63 Wallén P, Robertson B, Cangiano L, Löw P, Bhattacharjee A, Kaczmarek LK, Grillner S. Sodium-dependent potassium channels of a Slack-like subtype contribute to the slow afterhyperpolarization in lamprey spinal neurons. *J Physiol* 2007;585:75–90.

64 Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, Albrecht B, Bartholdi D, Beygo J, Di Donato N, Dufke A, Cremer K, Hempel M, Horn D, Hoyer J, Joset P, Röpke A, Moog U, Riess A, Thiel CT, Tzschach A, Wiesener A, Wohlleber E, Zweier C, Ekici AB, Zink AM, Rump A, Meisinger C, Grallert H, Sticht H, Schenck A, Engels H, Rappold G, Schröck E, Wieacker P, Riess O, Meitinger T, Reis A, Strom TM. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet* 2012;380:1674–82.

65 Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, Barth-Maron A, Greenberg ME, Stuhlmann T, Weinert S, Jentsch TJ, Pazzi M, Restifo LL, Talwar D, Erickson RP, Hammer MF. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. *Epilepsia* 2013;54:1270–81.

66 Kobayashi Y, Tohyama J, Kato M, Akasaka N, Magara S, Kawashima H, Ohashi T, Shiraishi H, Nakashima M, Saitsu H, Matsumoto N. High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders. *Brain Dev* 2015. Published Online First: 21 October 2015.

67 McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. *Lancet Neurol* 2015. Published Online First: 16 November 2015.

68 Bhattacharjee A, von Hehn CA, Mei X, Kaczmarek LK. Localization of the Na$^+$-activated K$^+$ channel Slick in the rat central nervous system. *J Comp Neurol* 2005;484:80–92.

69 Rizzi S, Knaus HG, Schwarzer C. Differential distribution of the sodium-activated potassium channels Slick and Slack in mouse brain. *J Comp Neurol* 2015. Published Online First: 20 November 2015.

70 Bausch AE, Dieter R, Nann Y, Hausmann M, Meyerdierks N, Kaczmarek LK, Ruth P, Lukowski R. The sodium-activated potassium channel Slack is required for optimal cognitive flexibility in mice. *Learn Mem* 2015;22:323–36.

71 Bhattacharjee A, Gan L, Kaczmarek LK. Localization of the Slack potassium channel in the rat central nervous system. *J Comp Neurol* 2002;454:241–54.

72 Biggin PC, Roosild T, Choe S. Potassium channel structure: domain by domain. *Curr Opin Struct Biol* 2000;10:456–61.

73 Choe S. Potassium channel structures. *Nat Rev Neurosci* 2002;3:115–21.

74 Yellen G. The voltage-gated potassium channels and their relatives. *Nature* 2002;419:35–42.

75 Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, Reid CA, Venkat A, Younkin DP, Dlugos DJ, Petrovski S, Goldstein DB, Dibbens LM, Scheffer IE, Berkovic SF, Petrou S. *KCNT1* gain of function in 2 epilepsy phenotypes is reversed by quinidine. *Ann Neurol* 2014;75:581–90.

76 Picard F, Mégevand P, Minotti L, Kahane P, Ryvlin P, Seeck M, Michel CM, Lantz G. Intracerebral recordings of nocturnal hyperkinetic seizures: demonstration of a longer duration of the pre-seizure sleep spindle. *Clin Neurophysiol* 2007;118:928–39.

77 Brown MR, Kronengold J, Gazula V-R, Chen Y, Strumbos JG, Sigworth FJ, Navaratnam D, Kaczmarek LK. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. *Nat Neurosci* 2010;13:819–21.

78 Bhattacharjee A, Joiner WJ, Wu M, Yang Y, Sigworth FJ, Kaczmarek LK. Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP. *J Neurosci* 2003;23:11681–91.

79 Yang B, Gribkoff VK, Pan J, Damagnez V, Dworetzky SI, Boissard CG, Bhattacharjee A, Yan Y, Sigworth FJ, Kaczmarek LK. Pharmacological activation and inhibition of Slack (Slo2.2) channels. *Neuropharmacology* 2006;51:896–906.

80 Sweetman SC, ed. *Martindale: the complete drug reference*. 37th edn. London, UK: Pharmaceutical Press, 2011.

81 Bean BP. The action potential in mammalian central neurons. *Nat Rev Neurosci* 2007;8:451–65.